Compare RENT & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RENT | MIST |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | Canada |
| Employees | N/A | 33 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.4M | 176.3M |
| IPO Year | 2021 | N/A |
| Metric | RENT | MIST |
|---|---|---|
| Price | $8.85 | $2.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 341.1K | ★ 10.0M |
| Earning Date | 12-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.35 | N/A |
| Revenue | ★ $314,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.72 | N/A |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | ★ 2.91 | N/A |
| 52 Week Low | $3.69 | $0.63 |
| 52 Week High | $10.11 | $3.06 |
| Indicator | RENT | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 72.17 | 42.75 |
| Support Level | $7.88 | $1.90 |
| Resistance Level | $9.30 | $2.22 |
| Average True Range (ATR) | 0.95 | 0.33 |
| MACD | 0.16 | -0.07 |
| Stochastic Oscillator | 85.50 | 33.20 |
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe to, or buy designer apparel and accessories. The company gives customers access to its unlimited closet through its subscription offering (Subscription) or the ability to rent a-la-carte through its reserve offering (Reserve). The company also gives its subscribers and customers the ability to buy its products through its Resale offering. The Closet in the Cloud offers a wide assortment of items for every occasion, from evening wear and accessories to ready-to-wear, workwear, denim, casual, maternity, outerwear, blouses, knitwear, loungewear, jewelry, handbags, activewear, and ski wear.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).